The Acute Effects of Cannabidiol on Physiological and Subjective Responses to Endurance Exercise: A Dose-Ranging Randomised Controlled Crossover Trial
Abstract Background Athletes report using cannabidiol (CBD), a non-intoxicating constituent of Cannabis sativa L., to enhance post-exercise recovery and manage other health conditions (e.g., poor sleep, anxiety, concussion). However, whether CBD influences performance-related outcomes remains unclea...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-08-01
|
| Series: | Sports Medicine - Open |
| Online Access: | https://doi.org/10.1186/s40798-025-00895-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226243307732992 |
|---|---|
| author | Ayshe Sahinovic Namson S. Lau Angelo Sabag Rebecca Gordon Amanda J. Cox Katie Walker Christopher Irwin Ben Desbrow Nathan Johnson Paul J. Austin Paul Haber Iain S. McGregor Danielle McCartney |
| author_facet | Ayshe Sahinovic Namson S. Lau Angelo Sabag Rebecca Gordon Amanda J. Cox Katie Walker Christopher Irwin Ben Desbrow Nathan Johnson Paul J. Austin Paul Haber Iain S. McGregor Danielle McCartney |
| author_sort | Ayshe Sahinovic |
| collection | DOAJ |
| description | Abstract Background Athletes report using cannabidiol (CBD), a non-intoxicating constituent of Cannabis sativa L., to enhance post-exercise recovery and manage other health conditions (e.g., poor sleep, anxiety, concussion). However, whether CBD influences performance-related outcomes remains unclear. This study investigated the acute effects of a low, nutraceutical (50 mg) and moderate, therapeutic (300 mg) dose of CBD on physiological and subjective responses to endurance exercise in trained runners. Results A randomised double-blind, placebo-controlled, crossover clinical trial was conducted at the University of Sydney between 24th October 2022 and 4th March 2024. Twenty-five participants (16 male; $${\dot{\text{V}}}$$ V ˙ O2max = 53.1 ± 7.5 mL·min kg−1) received either 0 (placebo), 50 or 300 mg CBD 1.5 h prior to completing a 60-min, submaximal intensity (~ 70% $${\dot{\text{V}}}$$ V ˙ O2max) treadmill run (RUN 1), followed by an incremental run to volitional exhaustion (RUN 2). Neither dose of CBD altered subjective responses (i.e., affective valence, enjoyment, perceived exertion, pain) during RUN 1, nor enjoyment, mood or anxiety following RUN 1 and 2 (p’s > 0.05). CBD also had a limited effect on exercise physiology and performance, with heart rate, exercise efficiency (i.e., $${\dot{\text{V}}}$$ V ˙ O2), $${\dot{\text{V}}}$$ V ˙ O2peak and time to exhaustion (TTE) unchanged relative to placebo (p’s > 0.05). However, 300 mg CBD decreased the respiratory exchange ratio during RUN 1 (p = 0.030) and 50 mg CBD increased blood glucose upon cessation of RUN 2 (p = 0.003), compared to placebo. There was no effect of either dose on plasma concentrations of muscle damage markers, creatine and myoglobin (p’s > 0.05), but a Treatment x Time x Sex interaction was identified for the gastrointestinal barrier function marker, lipopolysaccharide, with post hoc analyses revealing higher concentrations in females Post RUN 2 on 50 mg (p = 0.032), but not 300mg CBD (p = 1.000), compared to placebo. Conclusions CBD (50 mg, 300 mg; acute) does not appear to alter the subjective experience of submaximal intensity exercise, impact endurance performance (i.e., TTE) or have compelling effects on physiological responses to exercise. Use of CBD by athletes is, therefore, unlikely to be ergolytic or ergogenic at low to moderate doses. Trial registration The trial was approved by the Sydney Local Health District’s Human Research Ethics Committee (2021/ ETH11945; X21-0392) and registered prospectively with the Australia and New Zealand Clinical Trials Registry (ACTRN12622000717752). |
| format | Article |
| id | doaj-art-dd765cf8fbea4d70a2836b0bc6a85cac |
| institution | Kabale University |
| issn | 2198-9761 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Sports Medicine - Open |
| spelling | doaj-art-dd765cf8fbea4d70a2836b0bc6a85cac2025-08-24T11:31:47ZengSpringerOpenSports Medicine - Open2198-97612025-08-0111112510.1186/s40798-025-00895-wThe Acute Effects of Cannabidiol on Physiological and Subjective Responses to Endurance Exercise: A Dose-Ranging Randomised Controlled Crossover TrialAyshe Sahinovic0Namson S. Lau1Angelo Sabag2Rebecca Gordon3Amanda J. Cox4Katie Walker5Christopher Irwin6Ben Desbrow7Nathan Johnson8Paul J. Austin9Paul Haber10Iain S. McGregor11Danielle McCartney12Lambert Initiative for Cannabinoid Therapeutics, The University of SydneyThe Boden Initiative, Charles Perkins Centre, The University of SydneyCharles Perkins Centre, The University of SydneyLambert Initiative for Cannabinoid Therapeutics, The University of SydneySchool of Pharmacy and Medical Sciences, Griffith UniversityLambert Initiative for Cannabinoid Therapeutics, The University of SydneySchool of Allied Health, Sport and Social Work, Griffith UniversitySchool of Allied Health, Sport and Social Work, Griffith UniversityCharles Perkins Centre, The University of SydneySchool of Medical Sciences, Faculty of Medicine and Health, The University of SydneyCentral Clinical School, The University of SydneyLambert Initiative for Cannabinoid Therapeutics, The University of SydneyLambert Initiative for Cannabinoid Therapeutics, The University of SydneyAbstract Background Athletes report using cannabidiol (CBD), a non-intoxicating constituent of Cannabis sativa L., to enhance post-exercise recovery and manage other health conditions (e.g., poor sleep, anxiety, concussion). However, whether CBD influences performance-related outcomes remains unclear. This study investigated the acute effects of a low, nutraceutical (50 mg) and moderate, therapeutic (300 mg) dose of CBD on physiological and subjective responses to endurance exercise in trained runners. Results A randomised double-blind, placebo-controlled, crossover clinical trial was conducted at the University of Sydney between 24th October 2022 and 4th March 2024. Twenty-five participants (16 male; $${\dot{\text{V}}}$$ V ˙ O2max = 53.1 ± 7.5 mL·min kg−1) received either 0 (placebo), 50 or 300 mg CBD 1.5 h prior to completing a 60-min, submaximal intensity (~ 70% $${\dot{\text{V}}}$$ V ˙ O2max) treadmill run (RUN 1), followed by an incremental run to volitional exhaustion (RUN 2). Neither dose of CBD altered subjective responses (i.e., affective valence, enjoyment, perceived exertion, pain) during RUN 1, nor enjoyment, mood or anxiety following RUN 1 and 2 (p’s > 0.05). CBD also had a limited effect on exercise physiology and performance, with heart rate, exercise efficiency (i.e., $${\dot{\text{V}}}$$ V ˙ O2), $${\dot{\text{V}}}$$ V ˙ O2peak and time to exhaustion (TTE) unchanged relative to placebo (p’s > 0.05). However, 300 mg CBD decreased the respiratory exchange ratio during RUN 1 (p = 0.030) and 50 mg CBD increased blood glucose upon cessation of RUN 2 (p = 0.003), compared to placebo. There was no effect of either dose on plasma concentrations of muscle damage markers, creatine and myoglobin (p’s > 0.05), but a Treatment x Time x Sex interaction was identified for the gastrointestinal barrier function marker, lipopolysaccharide, with post hoc analyses revealing higher concentrations in females Post RUN 2 on 50 mg (p = 0.032), but not 300mg CBD (p = 1.000), compared to placebo. Conclusions CBD (50 mg, 300 mg; acute) does not appear to alter the subjective experience of submaximal intensity exercise, impact endurance performance (i.e., TTE) or have compelling effects on physiological responses to exercise. Use of CBD by athletes is, therefore, unlikely to be ergolytic or ergogenic at low to moderate doses. Trial registration The trial was approved by the Sydney Local Health District’s Human Research Ethics Committee (2021/ ETH11945; X21-0392) and registered prospectively with the Australia and New Zealand Clinical Trials Registry (ACTRN12622000717752).https://doi.org/10.1186/s40798-025-00895-w |
| spellingShingle | Ayshe Sahinovic Namson S. Lau Angelo Sabag Rebecca Gordon Amanda J. Cox Katie Walker Christopher Irwin Ben Desbrow Nathan Johnson Paul J. Austin Paul Haber Iain S. McGregor Danielle McCartney The Acute Effects of Cannabidiol on Physiological and Subjective Responses to Endurance Exercise: A Dose-Ranging Randomised Controlled Crossover Trial Sports Medicine - Open |
| title | The Acute Effects of Cannabidiol on Physiological and Subjective Responses to Endurance Exercise: A Dose-Ranging Randomised Controlled Crossover Trial |
| title_full | The Acute Effects of Cannabidiol on Physiological and Subjective Responses to Endurance Exercise: A Dose-Ranging Randomised Controlled Crossover Trial |
| title_fullStr | The Acute Effects of Cannabidiol on Physiological and Subjective Responses to Endurance Exercise: A Dose-Ranging Randomised Controlled Crossover Trial |
| title_full_unstemmed | The Acute Effects of Cannabidiol on Physiological and Subjective Responses to Endurance Exercise: A Dose-Ranging Randomised Controlled Crossover Trial |
| title_short | The Acute Effects of Cannabidiol on Physiological and Subjective Responses to Endurance Exercise: A Dose-Ranging Randomised Controlled Crossover Trial |
| title_sort | acute effects of cannabidiol on physiological and subjective responses to endurance exercise a dose ranging randomised controlled crossover trial |
| url | https://doi.org/10.1186/s40798-025-00895-w |
| work_keys_str_mv | AT ayshesahinovic theacuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT namsonslau theacuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT angelosabag theacuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT rebeccagordon theacuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT amandajcox theacuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT katiewalker theacuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT christopherirwin theacuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT bendesbrow theacuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT nathanjohnson theacuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT pauljaustin theacuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT paulhaber theacuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT iainsmcgregor theacuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT daniellemccartney theacuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT ayshesahinovic acuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT namsonslau acuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT angelosabag acuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT rebeccagordon acuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT amandajcox acuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT katiewalker acuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT christopherirwin acuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT bendesbrow acuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT nathanjohnson acuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT pauljaustin acuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT paulhaber acuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT iainsmcgregor acuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial AT daniellemccartney acuteeffectsofcannabidiolonphysiologicalandsubjectiveresponsestoenduranceexerciseadoserangingrandomisedcontrolledcrossovertrial |